Houston, United States
ImmunoGenesis, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on re-envisioning the treatment of "cold" tumors, particularly immune-excluded tumors. These tumors, which account for over half of all cancers, are resistant to current immunotherapies due to mechanisms that suppress the immune response. ImmunoGenesis has a deliberate drug development strategy targeting the pathology of immune-excluded tumors, designing therapies to overcome immune exclusion and drive an effective immune response.
Founded in 2019 and based in the United States, the company recently secured a $4.50M Venture Round investment on 27 June 2023 from the Cancer Focus Fund. With its focus on biotechnology, health care, health and wellness, and life sciences, ImmunoGenesis, Inc. is dedicated to addressing the significant unmet need in the treatment of cold tumors, offering a promising opportunity for investors in the healthcare and biopharmaceutical sectors.
